Journal
MUSCLE & NERVE
Volume 49, Issue 4, Pages 487-494Publisher
WILEY
DOI: 10.1002/mus.23951
Keywords
B10 cells; MG; FACS; MGFA; Rituximab
Categories
Funding
- National Basic Science Program of China [81230028]
- National Science Foundation of China [81171183, 2013CB966900]
- Muscular Dystrophy Association, US National Institutes of Health [R01AI083294]
Ask authors/readers for more resources
Introduction: A subset of regulatory B cells in humans and mice has been defined functionally by their ability to produce interleukin (IL)-10. We characterized IL-10-producing B (B10) cells in myasthenia gravis (MG) patients and correlated them with disease activity and responsiveness to rituximab therapy. Methods: Frequencies of B10 cells from MG patients and healthy controls were monitored by fluorescence-activated cell sorting (FACS). Results: MG patients had fewer B10 cells than controls, which was associated with more severe disease status. Moreover, patients who responded well to rituximab therapy exhibited rapid repopulation of B10 cells, whereas in patients who did not respond well to rituximab, B10 cell repopulation was delayed. The kinetics of B10 cells were related to the responsiveness to rituximab in MG. Conclusions: We have characterized a specific subset of B10 cells in MG patients which may serve as a marker for disease activity and responsiveness to immune therapy. Muscle Nerve 49:487-494, 2014
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available